Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market

Financial news outlet finfeed featured Regeneus’ Kyocera deal on the day of the announcement, offering in depth analysis of the company, the progress made so far in addressing the global pain market through its differentiated technologies, and the upcoming milestones investors can look forward to.

Read the full article via finfeed here.